Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations MIJ821 - NR2B negative allosteric modulator (NAM) Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04722666 (CMIJ821A12201) Depression (Major Depressive Disorder) Phase 2 195 Change from baseline to 24 hours in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS) MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 or 0.9% sodium chloride for 40 minutes IV infusion MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1 or 0.9% sodium chloride for 40 minutes IV infusion Participants with major depressive disorder who have suicidal ideation with intent Target Patients Read-out Milesstone(s) 2023 Publication TBD 89 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation